Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04833049 · ClinicalTrials.gov registry record · Phase 1
Study to Evaluate Absorption, Metabolism, and Excretion, of TAK-994 in 6 Healthy Male Adults
A Phase 1 study, sponsored by Takeda.
- Completed
- Registry status
- Phase 1
- Development phase
- 6
- Enrollment target
NCT04833049 is a Phase 1 study that has completed, run by Takeda. The registered enrollment target is 6 participants.
The verdict
NCT04833049, a Phase 1 study, has completed, sponsored by Takeda.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 6 participants
- Enrollment target
Study Summary
The aim of this study is to understand how TAK-994 is processed by the body. This study will require participants to stay at the clinical research unit for 3 weeks to be monitored after receiving TAK-994.
Interventions
- DRUG TAK-994 Oral Tablet
- DRUG [14C]TAK-994 Intravenous Infusion
- DRUG [14C]TAK-994 Oral Suspension
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 6 participants |
| Start Date | 2021-04-14 |
| Est. Completion | 2021-06-20 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04833049
The ClinicalTrials.gov registry entry for NCT04833049 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 6 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Takeda, which has 408 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which TAK-994 Oral Tablet is the first listed.
NCT04833049 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04833049 about?
NCT04833049 is a clinical study titled "Study to Evaluate Absorption, Metabolism, and Excretion, of TAK-994 in 6 Healthy Male Adults". The aim of this study is to understand how TAK-994 is processed by the body. This study will require participants to stay at the clinical research unit for 3 weeks to be monitored after receiving TAK-994.
What is the current status of trial NCT04833049?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 6 participants. The study started on 2021-04-14. Estimated completion is 2021-06-20.
What interventions are being tested in trial NCT04833049?
The interventions under investigation include: TAK-994 Oral Tablet (DRUG), [14C]TAK-994 Intravenous Infusion (DRUG), [14C]TAK-994 Oral Suspension (DRUG).
Who is sponsoring clinical trial NCT04833049?
This trial is sponsored by Takeda, which has 408 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.